Business
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31,
About this update from Context Therapeutics Inc.
[{"type":"image","alt":"Context Therapeutics Inc.","displaySize":"","headline":null,"caption":"Context Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YbSmZ9VBJ1k54h3C06aWkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85","width":300,"height":140}},"lazy":false},{"type":"text","content":"CTIM-76 and CT-95 in Phase 1 Clinical Trials","length":44,"tagName":"p"},{"type":"text","content":"Cash and cash equivalents of $89.4 million as of March 31, 2025","length":63,"tagName":"p"},{"type":"text","content":"Company expects its cash and cash equivalents will continue to fund operations into 2027","length":88,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights.","length":365,"tagName":"p"},{"type":"text","content":"Martin Lehr, CEO of Context, commented, “We continue to advance our clinical pipeline and are pleased to have two product candidates now in Phase 1 clinical trials — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody. We expect to report initial clinical data for CTIM-76 in the first half of 2026 and for CT-95 by mid-2026. Notably, we ended the first quarter of 2025 with $89.4 million in cash and cash equivalents, which we expect will provide the resources to fund our clinical programs into 2027. Looking ahead, we also plan to file an IND for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in mid-2026 as we continue to advance our portfolio of innovative T cell-engaging therapies for solid tumors.”","length":830,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Highlights and Subsequent Events","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In May 2025, announced ...